Bruce Nudell

In a report published Monday, Credit Suisse analyst Bruce Nudell initiated coverage on Mediwound Ltd. (NASDAQ: MDWD) with an Outperform rating and $18.00 price target. In the report, Credit Suisse noted, “MDWD is an Israeli therapeutics company with one approved product, NexoBrid (NXB) for severe...

In a report published Monday, Credit Suisse analyst Bruce Nudell adjusted estimates and raised the price target on Stryker Corporation (NYSE: SYK) from $77.00 to $84.00 following the MAKO Surgical Corp. (NASDAQ: MAKO) acquisition. Credit Suisse added MAKO Surgical to Stryker estimates, raising...

In a report published Monday, Credit Suisse analyst Bruce Nudell upgraded the rating on Baxter International (NYSE: BAX) from Neutral to Outperform, and raised the price target from $73.00 to $80.00. In the report, Credit Suisse noted, “We're upgrading BAX to OP from Neutral given the 3-month...

In a report published Tuesday, Credit Suisse analyst Bruce Nudell upgraded the rating on Zimmer Holdings (NYSE: ZMH) from Neutral to Outperform, and raised the price target from $90.00 to $100.00. In the report, Credit Suisse noted, “We lack insight into ZMH's 3Q results (reported 10/24), but...

In a report published Friday, Credit Suisse analyst Bruce Nudell upgraded Thoratec (NASDAQ: THOR) from Neutral to Outperform, and raised the price target from $35.00 to $43.00. In the report, Credit Suisse noted, “We believe THOR can grow sales ~11% over the next 3-4 years despite encroachment...

In a report published Friday, Credit Suisse analyst Bruce Nudell upgraded HeartWare (NASDAQ: HTWR) from Neutral to Outperform, but lowered the price target from $105.00 to $96.00. In the report, Credit Suisse noted, “Based on HTWR's 2Q results we estimate that the US LVAD market grew roughly 21...

In a report published Wednesday, Credit Suisse analyst Bruce Nudell initiated coverage on Baxter International (NYSE: BAX) with an Outperform rating and $81.00 price target. In the report, Credit Suisse noted, “We see BAX's solid top-line growth (4.6% organic growth in 2012-15, 1% ahead of...